Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | USP5 | P45974 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21847058 | 0.86 | ALDH1A1 (0.46) | KDM4EALDH1A1POLBHSD17B10SIGMAR1 | |
| SCHEMBL12793041 | 0.86 | POLB (0.44) | KDM4EALDH1A1PDE7APOLBHSD17B10 | |
| SCHEMBL3226408 | 0.86 | POLB (0.44) | KDM4EALDH1A1PDE7APOLBHSD17B10 | |
| SCHEMBL23173069 | 0.84 | POLB (0.42) | KDM4EALDH1A1PDE7APOLBHSD17B10 | |
| SCHEMBL3272642 | 0.83 | SIGMAR1 (0.51) | POLBHSD17B10SIGMAR1L3MBTL3L3MBTL1 | |
| SCHEMBL22191535 | 0.83 | SIGMAR1 (0.48) | PDE7APOLBHSD17B10SIGMAR1L3MBTL3 | |
| SCHEMBL3272638 | 0.83 | SIGMAR1 (0.51) | POLBHSD17B10SIGMAR1L3MBTL3L3MBTL1 | |
| SCHEMBL15190856 | 0.83 | SIGMAR1 (0.51) | POLBHSD17B10SIGMAR1L3MBTL3L3MBTL1 | |
| SCHEMBL22208127 | 0.83 | POLB (0.46) | KDM4EALDH1A1PDE7APOLBHSD17B10 | |
| SCHEMBL4777482 | 0.81 | SIGMAR1 (0.54) | POLBHSD17B10SIGMAR1L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| EP-2331518-A1 | NEW BRADYKININ B1 ANTAGONISTS | Evotec AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | KDM4E 2806/4885ALDH1A1 3283/4885PDE7A 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.